Onco-Innovations Income Statement

Financials in millions CAD. Fiscal year is May - April.

Millions CAD. Fiscal year is May - Apr.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023
Period Ending	Jul '26 Jul 31, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023
Revenue	0.09	0.11	0.07	-	-
Revenue Growth	7.18%	69.06%	-	-	-
Gross Profit	0.09	0.11	0.07	-	-
Selling, General & Admin	1.75	1.87	1.28	0.39	0
Research & Development	1.64	1.27	0.24	-	-
Operating Expenses	8.66	7.53	3.1	0.39	0
Operating Income	-8.57	-7.42	-3.03	-0.39	-0
Currency Exchange Gain (Loss)	-0	-0	-0.01	-	-
Other Non Operating Income (Expenses)	-2.9	-3.35	-1.63	-	-
EBT Excluding Unusual Items	-11.47	-10.78	-4.67	-0.39	-0
Asset Writedown	-	-	-2.76	-	-
Other Unusual Items	-	-	-0.13	-	-
Pretax Income	-11.47	-10.78	-7.56	-0.39	-0
Net Income	-11.47	-10.78	-7.56	-0.39	-0
Net Income to Common	-11.47	-10.78	-7.56	-0.39	-0
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	57	55	41	3	-
Shares Outstanding (Diluted)	57	55	41	3	-
Shares Change	25.92%	35.96%	1071.62%	-	-
EPS (Basic)	-0.20	-0.19	-0.19	-0.11	-
EPS (Diluted)	-0.20	-0.19	-0.19	-0.11	-
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023
Period Ending	Jul '26 Jul 31, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023
Gross Margin	100.00%	100.00%	100.00%	-	-
Operating Margin	-9431.99%	-6725.91%	-4646.69%	-	-
Profit Margin	-12625.19%	-9763.39%	-11580.58%	-	-
EBIT	-8.57	-7.42	-3.03	-0.39	-0